1623 Capital’s Precision BioSciences DTIL Stock Holding History

1623 Capital’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-409	Closed	-$127K	–	75
2021 Q1	$127K	Buy	+409	New	+$143K	0.05%	65

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1623 Capital's DTIL Position: Q2 2021 in Review

1623 Capital sold out of Precision BioSciences (DTIL) in Q2 2021, closing a stake of 409 shares — an estimated $127K sold.

1623 Capital first reported a position in DTIL in Q1 2021 and held it in 1 quarter. The position peaked at $127K in Q1 2021. 130 funds tracked by Wall St. Rank hold DTIL as of Q2 2021.

1623 Capital reported no remaining Precision BioSciences position as of Q2 2021 after selling out during the quarter.
1623 Capital sold 409 Precision BioSciences shares in Q2 2021, an estimated $127K.
1623 Capital first reported a position in Precision BioSciences in Q1 2021 and held it in 1 quarter.
1623 Capital's Precision BioSciences position peaked at $127K in Q1 2021.
130 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2021.

Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.